Opolski A, Wietrzyk J, Chrobak A, Marcinkowska E, Wojdat E, Kutner A, Radzikowski C
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Anticancer Res. 1999 Nov-Dec;19(6B):5217-22.
The antiproliferative in vitro activity of side-chain modified analogues of 1,25-dihydroxyvitamin D3 was examined in order to select compounds with potential antitumour activity. Analogues PRI-1906, PRI-1907, PRI-1909, PRI-2191, PRI-2192, PRI-2193 and PRI-2194 were examined for their antiproliferative activity in vitro against a spectrum of various human cancer cell lines using the MTT technique. In addition, analogues PRI-1906 and PRI-2191 were screened against cells of human leukaemia HL-60 line and against normal human skin fibroblasts. Calcitriol and these two analogues revealed strong antiproliferative activity against these two targets with maximal growth inhibition of 68% for HL-60 cells and of 60% for fibroblasts, and this effect was dose dependent. All analogues tested, except PRI-1909, revealed antiproliferative activity against human carcinoma cell lines of breast origin applied, namely against T47D and MCF-7. The maximal growth inhibition of 49% for T47D cell line and 39% for MCF-7 line was observed, and this effect was dose dependent. The inhibitory doses of the analogues tested were compared with the indices for calcitriol. Analogue PRI-1906 revealed the strongest antiproliferative activity against these four target cell lines (HL-60, fibroblasts, MCF-7, and T47D). The novel analogues of calcitriol, similarly to calcitriol, appeared to be not active against other human cancer cell lines tested (including those originated from lung, colon, prostate, urinary bladder, ovary, pancreas, stomach and kidney) revealing an antiproliferative activity not exceeding 20%. The mechanism of the observed antiproliferative effect of calcitriol and its analogues in vitro remains unclear, however, it may be related to their effect on cell differentiation. The appearance of antigen CD14 and CD11b expression after exposure to calcitriol and its new analogues confirmed their effect on cell differentiation.
为了筛选出具有潜在抗肿瘤活性的化合物,研究了1,25 - 二羟基维生素D3侧链修饰类似物的体外抗增殖活性。采用MTT技术检测了类似物PRI - 1906、PRI - 1907、PRI - 1909、PRI - 2191、PRI - 2192、PRI - 2193和PRI - 2194对一系列不同人类癌细胞系的体外抗增殖活性。此外,还对类似物PRI - 1906和PRI - 2191进行了针对人白血病HL - 60细胞系细胞以及正常人皮肤成纤维细胞的筛选。骨化三醇和这两种类似物对这两个靶点均显示出较强的抗增殖活性,对HL - 60细胞的最大生长抑制率为68%,对成纤维细胞的最大生长抑制率为60%,且这种作用呈剂量依赖性。除PRI - 1909外,所有测试的类似物对所应用的乳腺来源的人癌细胞系,即T47D和MCF - 7,均显示出抗增殖活性。观察到T47D细胞系的最大生长抑制率为49%,MCF - 7细胞系的最大生长抑制率为39%,且这种作用呈剂量依赖性。将测试类似物的抑制剂量与骨化三醇的指标进行了比较。类似物PRI - 1906对这四种靶细胞系(HL - 60、成纤维细胞、MCF - 7和T47D)显示出最强的抗增殖活性。与骨化三醇类似,骨化三醇的新型类似物对其他测试的人类癌细胞系(包括源自肺、结肠、前列腺、膀胱、卵巢、胰腺、胃和肾脏的细胞系)似乎无活性,其抗增殖活性不超过20%。然而,骨化三醇及其类似物体外抗增殖作用的机制仍不清楚,可能与其对细胞分化的影响有关。暴露于骨化三醇及其新类似物后抗原CD14和CD11b表达的出现证实了它们对细胞分化的作用。